BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

nab-paclitaxel: trial readouts and FDA decisions

6 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 7 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: SynerGene Therapeutics, Inc., Akeso, CStone Pharmaceuticals, Huabo Biopharm Co., Ltd., Gilead Sciences, Astellas Pharma Global Development, Inc., Biotheus Inc., Hoffmann-La Roche, SynerGene Therapeutics, Inc., Huabo Biopharm Co., Ltd., Astellas Pharma Global Development, Inc., Verastem, Inc., Panbela Therapeutics, Inc., DualityBio Inc., Revolution Medicines, Inc.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P2SynerGene Therapeutics, Inc.NCT02340117 Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic CancerMetastatic Pancreatic Canceractive not recruiting28
2026-12 est.P3AkesoNCT06767527 AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast CancerTriple-Negative Breast Cancer (TNBC)recruiting416
2027-01 est.P1/P2CStone PharmaceuticalsNCT06741644 A Phase I/II Study of CS2009 in Participants With Advanced Solid TumorsAdvanced Solid Tumorsrecruiting800
2027-01-15 est.P2Huabo Biopharm Co., Ltd.NCT07376629 A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBCTNBCenrolling by invitation60
2027-02 est.P3Gilead Sciences GILDNCT05382286 Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally AdTriple Negative Breast Cancer; PD-L1 Positiveactive not recruiting443
2026-12-30 est.P1/P2AkesoNCT06646055 AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic CancerMetastatic Pancreatic Ductal Adenocarcinomaactive not recruiting110

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10-31 est.P2Astellas Pharma Global Development, Inc.NCT03816163 A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic CancerPancreatic Cancer; Metastatic Pancreatic Cancer; Metastatic Pancreatic Adenocarcinomaactive not recruiting393
2026-10-30 est.P1/P2Biotheus Inc.NCT05918133 A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBCTNBCactive not recruiting42
2026-10-15P2Hoffmann-La RocheNCT05852691 A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-AdvancedBreast Cancercompleted83
2026-08-31 est.P1/P2Verastem, Inc. VSTMNCT05669482 Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic CancerKRAS Activating Mutation; Metastatic Cancer; Pancreas Cancer; Neoplasms Pancreatic; Malignant Neoplaactive not recruiting40
2026-08-29 est.P2/P3Panbela Therapeutics, Inc.NCT05254171 Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic CancerPancreatic Cancer Metastatic; Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer Stage IVrecruiting600
2026-08-12P3DualityBio Inc.NCT06018337 A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)Metastatic Breast Canceractive not recruiting541
2026-06 est.P3Revolution Medicines, Inc. RVMDNCT06625320 Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Cancer; PDAC; PDAC - Pancreatic Ductal Adenocarcinomaactive not recruiting500

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.